DOW Combat Readiness – Medical Research Program Translational Research Award
Agency: Defense Health Agency Contracting Activity - DHACA
- 12.420 -- Military Medical Research and Development
Open opportunityLast Updated: Jun 24, 2026
Important dates
- Closing: November 18, 2026
Award details
- Expected project funding: $4,370,000
- Expected awards: 3
Award min.
Not specified
Award max.
Not specified
- Funding opportunity number:HT942526CRRPTRA
- Cost sharing or matching requirement:No
- Funding instrument type:
- Cooperative agreement
- Grant
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Science technology and other research and development
- Category Explanation:Not specified
History
- Posted date: June 24, 2026
- Archive date: December 18, 2026
- Version: 1
Summary
Jump to documentsSummary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-impact translational research that will accelerate the movement of promising ideas and/or technologies in trauma care into solutions to maximize casualty survivability, improve patient care closer to the point of injury and/or trauma care guidelines. Preliminary data are required. Research using well-validated animal models is allowed.
Distinctive Features:
• **NEW for FY26** An investigator may be named as the Principal Investigator (PI) on only one FY26 CRRP TRA application.
• Research supported by the FY26 CRRP TRA must represent a mature, translational research effort with a minimum biomedical technology readiness level (TRL) of 4 or knowledge readiness level (KRL) of 4.
Eligibility
Miscellaneous
- Unrestricted
Additional information on eligibility
Documents
| File name | Description | Last updated |
|---|---|---|
| HT942526CRRPTRA_GG.pdf | FY26 CRRP TRA Program Announcement | Jun 24, 2026 07:53 PM UTC |
Agency contact information
Email: help@eBRAP.org
eBRAP Help Desk
Link to additional information
No additional information is available
